An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Seoul National University Hospital1,132 enrolled

Overview

The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.

Study Type

OBSERVATIONAL

Enrollment

1,132

Conditions

Pancreatic Cancer Neoadjuvant

Interventions

Neoadjuvant treatmentDRUG

Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC) * Between January 2007 and June 2021 at Seoul National University Hospital Exclusion Criteria: * Patients who had borderline resectable PDAC with arterial invasion * Patients who received chemotherapy as initial treatment and did not undergo surgery * Incomplete follow-up data for analysis

Outcomes

Primary Outcomes

Overall survival

the time from diagnosis to death from any cause or the date of the last visit

Time frame: From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.